Table 1 Baseline demographics and disease characteristics
Characteristics | Ranibizumab 0.5 mg VA only (Group I) | Ranibizumab 0.5 mg VA and/or OCT (Group II) | ||
|---|---|---|---|---|
Randomized set n = 335 | 12-month completers n = 151 | Randomized set n = 336 | 12-month completers n = 154 | |
Mean (SD) age, years | 73.9 (7.9) | 74.1 (8.10) | 75.3 (7.9) | 74.9 (7.9) |
Gender, Female, n (%) | 213 (63.6) | 91 (60.3) | 194 (57.7) | 93 (60.4) |
Race, Caucasian, n (%) | 320 (95.5) | 150 (99.3) | 325 (96.7) | 154 (100) |
Mean (SD) BCVA, ETDRS letters | 61.9 (12.84) | 60.9 (13.10) | 59.8 (12.64) | 60.2 (12.21) |
Mean (SD) CSFT, μm | 500.9 (203.58) | 517.7 (201.8) | 512.7 (193.80) | 515.3 (198.37) |
Mean (SD) time since first diagnosis of nAMD, weeks | 6.6 (41.74) | 8.3 (57.40) | 4.8 (15.65) | 5.5 (20.87) |
Mean (SD) central subfield volume on OCT, mm3 | 0.4 (0.16) | 0.4 (0.16) | 0.4 (0.15) | 0.4 (0.16) |
Presence of subretinal fluid on OCT, Yes, n (%) | 257 (76.7) | 126 (83.4) | 270 (80.4) | 132 (85.7) |
Presence of fluid beneath the retinal pigment epithelium on OCT, Yes, n (%) | 122 (36.4) | 59 (39.1) | 132 (39.3) | 59 (38.3) |
Presence of cysts on OCT, Yes, n (%) | 150 (44.8) | 77 (51.0) | 174 (51.8) | 78 (50.6) |
Presence of extrafoveal CNV lesions on FA, Yes, n (%) | 123 (36.7) | 56 (37.1) | 108 (32.1) | 53 (34.4) |
Lesion type on FA, n (%) | ||||
- 100% classic | 73 (21.8) | 40 (26.5) | 72 (21.4) | 35 (22.7) |
- Predominantly classic | 20 (6.0) | 7 (4.6) | 27 (8.0) | 14 (9.1) |
- Minimally classic | 36 (10.7) | 18 (11.9) | 33 (9.8) | 16 (10.4) |
- Occult with no classic component | 123 (36.7) | 61 (40.4) | 114 (33.9) | 55 (35.7) |